Health ❯ Metabolic Disorders

Obesity

Type 2 Diabetes Diabetes Fatty Liver Disease Dental Health Pharmacological Advances Epigenetics Diet-induced Obesity Drug Regulation Hormonal Imbalance Treatment Options Therapeutics Adipogenesis Comorbidities Gestational Diabetes Risk Factors Cardiovascular Disease

Lilly Combo of Zepbound and Taltz Tops Taltz Alone in Late-Stage Psoriasis Trials

The company plans publication followed by regulatory discussions.

Lilly and Nimbus Strike Multi-Year AI Deal for Oral Obesity Drugs

Prolynx Raises $70 Million to Advance Ultra-Long-Acting Obesity Drugs

Review Spotlights Senotherapeutics as Emerging Approach for Metabolic Disease

PNAS Study Identifies CHP1 as Master Regulator of Lipid Droplet Growth

Single CRISPR Treatment Lets Mice Produce Weight-Loss Drug for Over Six Months